Literature DB >> 9482429

Position statement: whole bowel irrigation. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.

M Tenenbein.   

Abstract

In preparing this Position Statement, all relevant scientific literature was identified and reviewed critically by acknowledged experts using agreed criteria. Well-conducted clinical and experimental studies were given precedence over anecdotal case reports and abstracts were not usually considered. A draft Position Statement was then produced and subjected to detailed peer review by an international group of clinical toxicologists chosen by the American Academy of Clinical Toxicology and the European Association of Poisons Centres and Clinical Toxicologists. The Position Statement went through multiple drafts before being approved by the boards of the two societies and being endorsed by other societies. The Position Statement includes a summary statement for ease of use and is supported by detailed documentation which describes the scientific evidence on which the Statement is based. Whole bowel irrigation (WBI) should not be used routinely in the management of the poisoned patient. Although some volunteer studies have shown substantial decreases in the bioavailability of ingested drugs, no controlled clinical trials have been performed and there is no conclusive evidence that WBI improves the outcome of the poisoned patient. Based on volunteer studies, WBI may be considered for potentially toxic ingestions of sustained-release or enteric-coated drugs. There are insufficient data to support or exclude the use of WBI for potentially toxic ingestions of iron, lead, zinc, or packets of illicit drugs; WBI remains a theoretical option for these ingestions. WBI is contraindicated in patients with bowel obstruction, perforation, ileus, and in patients with hemodynamic instability or compromised unprotected airways. WBI should be used cautiously in debilitated patients, or in patients with medical conditions that may be further compromised by its use. A single dose of activated charcoal administered prior to WBI does not appear to decrease the binding capacity of charcoal or to alter the osmotic properties of WBI solution. Administration of charcoal during WBI appears to decrease the binding capacity of charcoal.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9482429     DOI: 10.3109/15563659709162571

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  15 in total

Review 1.  Management of self poisoning.

Authors:  A L Jones; G Volans
Journal:  BMJ       Date:  1999-11-27

2.  Managing self poisoning. Gastric lavage is perhaps more important in developing countries.

Authors:  M D Bhattarai
Journal:  BMJ       Date:  2000-03-11

3.  New approach to treating Escherichia coli O157:H7?

Authors:  P Beaupré
Journal:  Can Fam Physician       Date:  2000-07       Impact factor: 3.275

Review 4.  Common culprits in childhood poisoning: epidemiology, treatment and parental advice for prevention.

Authors:  M A McGuigan
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.022

Review 5.  Poisoning in children 3: common medicines.

Authors:  M Riordan; G Rylance; K Berry
Journal:  Arch Dis Child       Date:  2002-11       Impact factor: 3.791

Review 6.  Poisoning in children 1: general management.

Authors:  M Riordan; G Rylance; K Berry
Journal:  Arch Dis Child       Date:  2002-11       Impact factor: 3.791

Review 7.  Phenytoin poisoning.

Authors:  Simon Craig
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

8.  [Acute poisoning in adults].

Authors:  L Weidhase; H Hentschel; L Mende; G Schulze; S Petros
Journal:  Internist (Berl)       Date:  2014-03       Impact factor: 0.743

Review 9.  [Initial diagnosis and treatment for poisoning].

Authors:  S Pemmerl
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-08-15       Impact factor: 0.840

10.  Acute iron ingestion.

Authors:  Tansu Sipahi; Cemsit Karakurt; Arzu Bakirtas; Betül Tavil
Journal:  Indian J Pediatr       Date:  2002-11       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.